ADVFN

kittybiscuits 31/1/2025 07:24 Read Full Thread Reply You haven’t got it right for 3 years! You have consistently said it’ll be zero pence for 3 years and haven’t been right once. Moreover you tell so many lies on a daily basis, you are bound to be right at some point! Even a clock with no batteries is right twice a day. Read Full Thread Reply
neutralpov 30/1/2025 21:30 Read Full Thread Reply Jeannie: "Isn't it odd how NPOV has got the EDEN shate price consistently correct for 3 years but they all hate and mock him?" Answer: This is an insignificant obscure tadpole company, expertise mainly in puffery RNSs. Not in sales. No one is interested in it. There aren't many different humans here on this obscure discussion board, one multi-ID PoS evidently paid to tell lies about its prospects, and a few trapped bulls, several also multi-ID, desperate to engineer a spike. ARE YOU STILL SURPRISED THAT THE OBVIOUS TRUTH GETS SO MUCH HATE HERE? 30 years without profits, let alone (haha) dividends, and a disgraceful share price chart... all plain to see, obvious to even the most meagre intellect. ROTFL! Read Full Thread Reply
kittybiscuits 30/1/2025 20:03 Read Full Thread Reply And likewise, I expect one day you will slip away and never be heard of again once the share price climbs. The board won’t be as funny then, but your presence won’t be missed. Maybe you make your own tracks knowing you missed out. Read Full Thread Reply
kittybiscuits 30/1/2025 14:09 Read Full Thread Reply No further evidence is required. Just look at any of the thousands of posts over the last 3 years. On a stock he doesn’t even own!! Read Full Thread Reply
alchemy 30/1/2025 12:41 Read Full Thread Reply Very good ; and very good ! Read Full Thread Reply
alchemy 30/1/2025 11:53 Read Full Thread Reply Oh So when might the gun go off? Bearing in mind my limited knowledge is Ecovolex in the parallel delay universe ? Read Full Thread Reply
supersonico 30/1/2025 08:42 Read Full Thread Reply supersonico - 03 Dec 2019 - 15:33:50 - 7197 of 19826 Eden Research - EDEN Investing, you say 'I very much doubt others will co-ordinate all that you suggest'. Who are the 'others' you mention? If I was not under strict self imposed NDAs myself I could quite easily quote references to further substantiate my assertions regarding a shared formulation issue. I have been the most consistent and accurate of this position for easily two years now and despite comfort updates from Eden my theory on parallel delays remains intact. Read Full Thread Reply
supersonico 30/1/2025 08:41 Read Full Thread Reply supersonico - 29 Mar 2021 - 09:42:39 - 8975 of 19826 Eden Research - EDEN In short expect Parallel Parallel delays. Read Full Thread Reply
kittybiscuits 29/1/2025 22:03 Read Full Thread Reply You are a total ignorant moron. Read Full Thread Reply
kittybiscuits 29/1/2025 06:36 Read Full Thread Reply Yeah, yeah, yeah. More lies from NPOV. Read Full Thread Reply
neutralpov 28/1/2025 23:48 Read Full Thread Reply Thank you, supersonico. In general, it may be handy to keep an eye on what mad people and crooks do....... I will take only partial credit for BGF's Seeing The Light. But if one aggressive phone call from an (alleged) aggrieved BGF holder can accomplish so much, it must have been being considered already as a dump target, BGF, the only respectable institutional investor, departing, and the Trough of Directors increasing its aggregate holding by a third to a still paltry 1.34%, aside, please summarise this extraordinarily long series of C&Ps. Give us a Movements version which wholly ignores aggregators like Hargreaves Lansdown, Interactive Investor, Gresham House, Finn and other nominee company operators. I know from what you shared earlier that you have access to more than RNSs and statutorily-compelled disclosure documents; how you do does not concern me. Could you please put here or PM me with a list of the ten private "investors" (gurgling chuckle!!!) with most exposure to this zerobound coprophiliac's paradise. Thank you. It will be helpful as we move to the endgame for a few window-lickers.... ;-) Read Full Thread Reply
supersonico 28/1/2025 18:38 Read Full Thread Reply NUMBER OF AIM SECURITIES IN ISSUE As of 28 January 2025, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 21 December 2024, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,608,629 10.61% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 44,756,732 8.39% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,201,307 5.66% Atul Unadkat 23,486,291 4.40% Unicorn Asset Management 23,076,923 4.33% J M Finn 22,381,562 4.20% Rathbones 21,567,400 4.04% Amati Global Investors 16,744,070 3.14% As of 28 January 2025, the directors' shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital A Abrey 2,314,732 0.43% S Smith 1,913,117 0.36% L van der Broek 1,621,808 0.30% R Cridland 745,552 0.14% D McAllan 323,017 0.11% ........................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 June 2024, the number of shares in issue was 533,352,523. As of 21 June 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,037,526 10.51% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 41,915,712 7.86% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,964,424 4.31% JM Finn Nominees Limited 19,955,562 3.74% Amati Global Investors 16,744,070 3.14% Name Number of shares % of the issued ordinary share capital A Abrey 1,774,192 0.33% L van der Broek 1,621,808 0.30% S Smith 1,192,577 0.22% R Cridland 745,552 0.14% .................................... NUMBER OF AIM SECURITIES IN ISSUE As of 3 January 2024, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 53,364,313 10.01% Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Interactive Investor 33,363,457 6.26% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,099,924 4.14% JM Finn Nominees Limited 20,147,562 3.78% Amati Global Investors 16,744,070 3.14% BGF Investment Management Limited 16,000,576 3.00% ............................ As of 20 July 2023, the number of shares in issue was 381,108,607. SIGNIFICANT SHAREHOLDERS As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 45,307,219 11.89% Sipcam Oxon S.p.A. 37,614,830 9.87% Interactive Investor 31,957,945 8.39% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% BGF Investment Management Limited 20,233,000 5.31% JM Finn Nominees Limited 19,635,562 5.15% Atul Unadkat 18,811,765 4.94% Rathbone Nominees Limited 13,661,661 3.58% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% HSDL Stockbrokers 12,436,733 3.26% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% ................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 March 2023, the number of shares in issue was 380,858,607. SIGNIFICANT SHAREHOLDERS As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 51,733,000 13.58% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 31,737,596 8.33% Gresham House Asset Management Limited 27,845,445 7.31% Interactive Investor 25,172,555 6.61% Canaccord Genuity Group Inc 22,584,000 5.93% JM Finn Nominees Limited 19,839,762 5.21% Atul Unadkat 18,117,567 4.76% Rathbone Nominees Limited 15,621,872 4.10% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% SHARES NOT IN PUBLIC HANDS In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands. ................................................................................. Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% ...................................................................................................................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ..................................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% ...................................................................................................................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ..................................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN Selling yes..but it's a dribble which has been bought by Atul etal. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% ...................................................................................................................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ..................................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% 1 Read Full Thread Reply
supersonico 28/1/2025 18:33 Read Full Thread Reply NUMBER OF AIM SECURITIES IN ISSUE As of 28 January 2025, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 21 December 2024, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,608,629 10.61% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 44,756,732 8.39% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,201,307 5.66% Atul Unadkat 23,486,291 4.40% Unicorn Asset Management 23,076,923 4.33% J M Finn 22,381,562 4.20% Rathbones 21,567,400 4.04% Amati Global Investors 16,744,070 3.14% As of 28 January 2025, the directors' shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital A Abrey 2,314,732 0.43% S Smith 1,913,117 0.36% L van der Broek 1,621,808 0.30% R Cridland 745,552 0.14% D McAllan 323,017 0.11% Read Full Thread Reply
investingisatrickygame 28/1/2025 14:22 Read Full Thread Reply hybrasil. I think the article you are referring to is this one from June 2023 Read Full Thread Reply
hybrasil 28/1/2025 13:50 Read Full Thread Reply My attention was drawn to the share by a Joanne Harte article some years ago. I think every share has its time and I’m obviously hoping the time for Eden is now! Read Full Thread Reply
alchemy 28/1/2025 13:35 Read Full Thread Reply Thank you for health warning . The context is slightly different font you think? Read Full Thread Reply
erinvale1 28/1/2025 13:30 Read Full Thread Reply Don’t be fooled. Directors have purchased in the past. No effect: the share price continues to decline. Read Full Thread Reply

Showing 20226 to 20242 of 20275 messages

Eden Research plc Director/PDMR Shareholdings

Eden Research plc 28 January 2025 28 January 2025 Eden Research plc ("Eden" or "the Company") Director/PDMR Shareholdings Eden...

TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal

The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Al ...

Eden Research plc Trading Update

Eden Research plc 13 January 2025 The information contained within this announcement is deemed to constitute inside information as stipulated...

Eden Research plc Regulatory approval for Novellus+ in Mexico

Eden Research plc 20 December 2024 The information contained within this announcement is deemed to constitute inside information as stipulated...

Eden Research plc Appointment of Distributor in Austria

Eden Research plc 16 December 2024 The information contained within this announcement is deemed to constitute inside information as stipulated...

Eden Research plc Mevalone Organic Input Registration in Germany

Eden Research plc 11 December 2024 11 December 2024 Eden Research ("Eden" or "the Company") Mevalone® included in Organic Input List...

Eden Research plc Trading Update

Eden Research plc 07 November 2024 The information contained within this announcement is deemed to constitute inside information as stipulated...

Eden Research plc Ecovelex Approval in Italy

Eden Research plc 07 November 2024 As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute...

Eden Research plc OTCQB exchange update

Eden Research plc 08 October 2024 8 October 2024 Eden Research Plc ("Eden" or "Company") OTCQB exchange update Eden Research plc...

Eden Research half-year revenue surges nearly 75% despite rising costs

Eden Research PLC on Monday said its half-year revenue has jumped nearly 75% higher than last year as sales grow, des ...

Eden Research plc Half yearly Report

Eden Research plc 23 September 2024 The information contained within this announcement is deemed to constitute inside information as...

Eden Research plc Notice of Results

Eden Research plc 20 September 2024 20 September 2024 Eden Research Plc ("Eden" or "Company") Notice of Results Eden Research plc...

Eden Research plc Nematicide Approval in Greece

Eden Research plc 02 September 2024 2 September 2024 Eden Research Plc ("Eden" or "Company") Nematicide Approval in Greece Eden...

Eden Research plc Appointment of new Head of Regulatory Affairs

Eden Research plc 15 August 2024 15 August 2024 Eden Research Plc ("Eden" or "Company") Appointment of new Head of Regulatory Affairs ...

Eden Research hails approval of biofungicide Mevalone in Germany

Eden Research PLC on Tuesday celebrated the grant of regulatory authorisation for use of its flagship biofungicide, M ...

Company description

Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 3.75p. Over the last year, Eden Research shares have traded in a share price range of 3.50p to 6.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £20 million. Eden Research has a price to earnings ratio (PE ratio) of -3.07.

Type	Ordinary Share
Share ISIN	GB0001646941
Sector	Biological Pds,ex Diagnstics
Bid Price	3.70
Offer Price	3.80
Open	3.75
Shares Traded	7,800
Last Trade	08:00:00

Low - High	3.75 - 3.75
Turnover	3.19M
Profit	-6.49M
EPS - Basic	-0.0122
PE Ratio	-3.07
Market Cap	20M

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Eden Research Plc (EDEN)

Eden Research plc Director/PDMR Shareholdings

TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal

Eden Research plc Trading Update

Eden Research plc Regulatory approval for Novellus+ in Mexico

Eden Research plc Appointment of Distributor in Austria

Eden Research plc Mevalone Organic Input Registration in Germany

Eden Research plc Trading Update

Eden Research plc Ecovelex Approval in Italy

Eden Research plc OTCQB exchange update

Eden Research half-year revenue surges nearly 75% despite rising costs

Eden Research plc Half yearly Report

Eden Research plc Notice of Results

Eden Research plc Nematicide Approval in Greece

Eden Research plc Appointment of new Head of Regulatory Affairs

Eden Research hails approval of biofungicide Mevalone in Germany

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Eden Research Plc (EDEN) Forum

Eden Research Plc (EDEN)

Discussion Insights

News Insights

Eden Research Share Discussion Threads

News

Eden Research plc Director/PDMR Shareholdings

TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal

Eden Research plc Trading Update

Eden Research plc Regulatory approval for Novellus+ in Mexico

Eden Research plc Appointment of Distributor in Austria

Eden Research plc Mevalone Organic Input Registration in Germany

Eden Research plc Trading Update

Eden Research plc Ecovelex Approval in Italy

Eden Research plc OTCQB exchange update

Eden Research half-year revenue surges nearly 75% despite rising costs

Eden Research plc Half yearly Report

Eden Research plc Notice of Results

Eden Research plc Nematicide Approval in Greece

Eden Research plc Appointment of new Head of Regulatory Affairs

Eden Research hails approval of biofungicide Mevalone in Germany

Company description

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free